• Home
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), 1-5 November 2023 in San Diego, CA, USA

by admin | Nov 9, 2023 | Immunobody, Vaccines

Heather Shaw, Poulam Patel, Miranda Payne, Satish Kumar, Sarah Danson, Martin Highley, Clare Barlow, Robert Miller, Fayaz Master and Lindy Durrant

Scancell announces late-breaking abstract presenting positive data from the first stage in its Phase 2 SCOPE trial

by admin | Nov 1, 2023 | Latest News, Regulatory News, SCIB1

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Preliminary Results for the year ended 30 April 2023

by admin | Oct 31, 2023 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Interim Report 31st October 2023

by admin | Oct 31, 2023 | Financial Info

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Vaccination with post-translational modified, homocitrullinated peptides induces CD8 T-cell responses that mediate antitumor immunity

by admin | Oct 26, 2023 | Moditope, Vaccines

Sabaria Shah, Katherine W Cook, Peter Symonds, Juliane Weißer, Anne Skinner, Abdullah Al Omari, Samantha J Paston, Ian Pike, Lindy G Durrant, Victoria A Brentville ABSTRACT:Background: Post-translational modification of proteins has the potential to alter the ability...
« Older Entries
Next Entries »

Recent Posts

  • Active Immunotherapy: Ready For Prime Time
  • Strategic transactions to unlock longer-term value
  • Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
  • iSCIB1+ pivotal trial plans advancing
  • AACR (American Association for Cancer Research) Annual Meeting, April 2026, San Diego, California

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy